Fertility Drugs Market 2022-2028

Description

List of Tables

Title:Global Fertility Drugs Market Size, Share & Trends Analysis Report by Gender Type (Female Fertility Treatment, Male Fertility Treatment) by Treatment Type (Hormonal, In Vitro Fertilization(IVF), Intra Cytoplasmic Sperm Injection(ICSI), Intrauterine Insemination(IUI), Alternative and Complementary Treatment) by Infertility Type (Problem With Ovulating, Unexplained Infertility, Blocked Or Damaged Tubes, Endometriosis, Polycystic Ovarian Syndrome) Forecast 2022-2028.

The global fertility drugs market is anticipated to grow at a substantial CAGR of around 5.1% during the forecast period. The rising awareness towards the fertility treatment along with increase in healthcare expenditure in emerging economies is propelling the growth of fertility drugs market. The increase in expenditure on healthcare is mainly supported by the need among individuals for quality healthcare services. According to the statistics by the World Bank, the current health expenditure (% of GDP) around the world increased from 8.63% in 2000 to 9.84% in 2019. Rising healthcare expenditure is allowing a large number of people to access advanced healthcare facilities such as IVF, intra cytoplasmic sperm injection (ICSI), and intrauterine insemination (IUI), which in turn, is contributing to the growth of global fertility drug market.

The global fertility drug market is segmented on the basis on gender type, treatment type and infertility type. Based on gender type, the market is segmented into female fertility treatment, male fertility treatment. The male fertility treatment segment is expected to grow at the fastest rate; the growth is attributed to the increasing incidence of infertility, high adoption of assisted reproductive technology (ART), and technological advancements. According to a report published by National Institute of Health (NHI) in 2019, stated that 8% to 10% of the couples are affected by infertility making it a serious health issue. Based on treatment type, the market is sub-segmented into hormonal, in vitro fertilization (IVF), intra cytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), and alternative and complementary treatment. Based on infertility type, the market is sub-segmented into a problem with ovulating, unexplained infertility, blocked or damaged tubes, endometriosis, and polycystic ovarian syndrome.

Geographically market is segmented into: North America, Europe, Asia Pacific, and the Rest of the World. Asia-Pacific is estimated to contribute significantly to the growth of the market. China and India are the major contributors to the growth of the Asia-Pacific fertility drug market. The major factor that contributes to the growth of the market is the high adoption of costlier treatment, the availability of immense advanced fertility clinics, and the well-established healthcare infrastructure fueling the growth of the global fertility drug market to a large extent.

The major companies serving the global fertility drugs market F. Hoffmann-La Roche Ltd., Ferring Pharmaceuticals Inc., Johnson & Johnson Pvt. Ltd., Leadiant Biosciences Inc., and Merck & Co. Pharmaceutical Co., Noven Pharmaceutical organon, Inc., Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2021, Unified Women's Healthcare announced that it has entered into a definitive partnership with CCRM fertility. With this partnership the companies are providing an integrated fertility services platform, helping meet the demand for fertility treatment, and assist serve the patients across the spectrum of women's healthcare.

Research Methodology

The market study of the global fertility drugs market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.

Whitepapers, research papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Fertility Drugs Market Research and Analysis by Gender Type
Global Fertility Drugs Market Research and Analysis by Treatment Type
Global Fertility Drugs Market Research and Analysis by Infertility Type

The Report Covers:

Comprehensive research methodology of the global fertility drugs market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global fertility drugs market.
Insights about market determinants that are stimulating the global fertility drugs market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2026634

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global Fertility Drug Market
Recovery Scenario of Global Fertility Drug Market
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. BY Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight and Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key CompanyAnalysis

4. Market Determinants

4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation

5.1. Global Fertility Drug Market by Gender Type
- 5.1.1. Female Fertility Treatment
- 5.1.2. Male Fertility Treatment
5.2. Global Fertility Drug Market by Treatment Type
- 5.2.1. Hormonal
- 5.2.2. In Vitro Fertilization(IVF)
- 5.2.3. Intra Cytoplasmic Sperm Injection(ICSI)
- 5.2.4. Intrauterine Insemination(IUI)
- 5.2.5. Alternative and Complementary Treatment
5.3. Global Fertility Drug Market by Infertility Type
- 5.3.1. Problem with Ovulating
- 5.3.2. Unexplained Infertility
- 5.3.3. Blocked or Damaged Tubes
- 5.3.4. Endometriosis
- 5.3.5. Polycystic Ovarian Syndrome

6. Regional Analysis

6.1. North America
- 6.1.1. United States
- 6.1.2. Canada
6.2. Europe
- 6.2.1. UK
- 6.2.2. Germany
- 6.2.3. Italy
- 6.2.4. Spain
- 6.2.5. France
- 6.2.6. Rest of Europe
6.3. Asia-Pacific
- 6.3.1. China
- 6.3.2. India
- 6.3.3. Japan
- 6.3.4. South Korea
- 6.3.5. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles

7.1. Baxter Healthcare Corp.
7.2. Bayer AG
7.3. Eli Lilly
7.4. Emd Serono Inc.
7.5. F. Hoffmann-La Roche Ltd
7.6. Ferring Pharmaceuticals Inc.
7.7. Johnson & Johnson Pvt. Ltd
7.8. Leadiant Biosciences Inc.
7.9. Merck & Co. Pharmaceutical Co.
7.10. Noven Pharmaceuticalorganon, Inc.
7.11. Pfizer Inc.
7.12. Procter & Gamble Pharmaceuticals
7.13. Solvay
7.14. Takeda Pharmaceutical Co. Ltd.
7.15. Teva Pharmaceutical Industries Ltd.